EBIT (Quarterly)

EBIT: Income before interest and taxes.

ANI Pharmaceuticals, Inc. (ANIP) had EBIT of $34.77M for the most recently reported fiscal quarter, ending 2025-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-12-31

Income Statement Financials
Revenue	$247.06M
Net Income	$27.49M
Cost of Goods Sold	$100.27M
Gross Profit	$146.79M
Operating Expenses	$212.29M
Operating Income	$34.77M
Non-Operating Income/Expense	$-3.29M
Pre-Tax Income	$31.48M
Normalized Pre-Tax Income	$31.48M
Income after Taxes	$27.49M
Income from Continuous Operations	$27.49M
Consolidated Net Income/Loss	$27.49M
Normalized Income after Taxes	$27.49M
EBIT	$34.77M
EBITDA	$57.38M
Weighted-Average Shares Outstanding (Basic)	20.05M
Weighted-Average Shares Outstanding (Diluted)	21.23M
Earnings per Share (EPS) (Basic)	$1.24
Earnings per Share (EPS) (Diluted)	$1.14
Balance Sheet Financials
Current Assets	$753.12M
Property, Plant, and Equipment	$62.48M
Long-Term Assets	$687.26M
Total Assets	$1.44B
Current Liabilities	$278.11M
Long-Term Debt	$599.77M
Long-Term Liabilities	$621.54M
Total Liabilities	$899.65M
Common Equity	$540.72M
Tangible Shareholders Equity	$-1.28M
Shareholders Equity	$540.72M
Common Shares Outstanding	22.50M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$185.22M
Cash Flow from Investing Activities	$-34.32M
Cash Flow from Financial Activities	$-9.94M
Beginning Cash	$144.89M
End Cash	$285.62M
Increase/Decrease in Cash	$140.73M
Stock-Based Compensation	$37.93M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	$-1.16M
Fundamental Metrics & Ratios
Current Ratio	2.71
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.53
Debt to Equity Ratio	1.14
Gross Margin	59.42%
Operating Margin	14.07%
EBIT Margin	14.07%
EBITDA Margin	--
Pre-Tax Profit Margin	12.74%
Profit Margin	11.13%
Free Cash Flow	$171.39M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.17
Inventory Turnover	0.70
Receiveable Turnover	0.88
Days Sales in Receivables	102.39
Return on Equity	5.08%
Return on Tangible Equity	-2144.23%
Return on Assets	1.91%
Return on Investments	2.41%
Book Value Per Share	$24.03
Free Cash Flow per Share	$8.07
Operating Cash Flow per Share	$8.73

Data from Zacks Investment Research, Inc.